Liquid biopsy in peritoneal carcinomatosis from colorectal cancer: current evidence and future perspectives

Peritoneal carcinomatosis from colorectal cancer (PC-CRC) is a challenging condition associated with poor outcomes, even with aggressive treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). One of the main challenges is the lack of reliable biomarkers to...

Descripción completa

Detalles Bibliográficos
Autores: Martelli, Valentino, Vidal, Joana, Salvans Ruiz, Silvia, Fernández, Concepción, Badia-Ramentol, Jordi, Linares, Jenniffer, Jiménez Gómez, Marta, Sibilio, Annarita, Gibert Fernandez, Joan, 1988-, Pérez, Marina, Bellosillo Paricio, Beatriz, Calon, Alexandre, Pietrantonio, Filippo, Iglesias Coma, Mar, Pascual Damieta, Marta, Montagut Viladot, Clara
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:dnet:recercat____::a21d4b105f3b32c33f26256ec61b47cc
Acceso en línea:https://hdl.handle.net/10230/72978
http://dx.doi.org/10.3390/cancers17091461
Access Level:acceso abierto
Palabra clave:Circulating tumor DNA
Metastatic colorectal cancer
Peritoneal carcinomatosis
Peritoneal tumor DNA
Precision medicine
Descripción
Sumario:Peritoneal carcinomatosis from colorectal cancer (PC-CRC) is a challenging condition associated with poor outcomes, even with aggressive treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). One of the main challenges is the lack of reliable biomarkers to guide personalized treatment decisions. Circulating tumor DNA (ctDNA) in plasma has recently emerged as a promising tool in colorectal cancer (CRC) management. It detects residual disease after surgery in early-stage CRC and tracks mutations, treatment response, and resistance in metastatic CRC (mCRC). For PC-CRC, ctDNA, along with peritoneal tumor DNA (ptDNA) detected in peritoneal fluid, could offer significant insights for guiding treatment. These biomarkers have potential to improve disease monitoring and outcomes in this challenging context. This review examines the strengths, limitations, and future applications of liquid biopsy for PC-CRC care.

Similares en LA Referencia